The Phase 1 data are early but positive for a novel mechanism. Watch for ASCO presentation details on May 30 and any subsequent partnership or financing announcements. The stock may see volatility around the ASCO data release.
OLMA drugs
OLMA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 22 $13.68entry
- T+1 · 6mo ago −0.95%α −1.54% · $13.55
- T+5 · 6mo ago −7.09%α −8.77% · $12.71
- T+20 · 5mo ago −25.51%α −24.10% · $10.19
- T+60 · 3mo ago −22.15%α −25.34% · $10.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Olema Oncology announced preliminary Phase 1 data for OP-3136, a KAT6 inhibitor, showing acceptable tolerability and early anti-tumor activity across solid tumors. The data will be presented at ASCO 2026. While the safety profile and tumor shrinkage in 13 of 19 evaluable patients are encouraging, the sample is small and heavily pretreated, limiting immediate commercial read-through.
Key Facts
- OP-3136 monotherapy showed no dose-limiting toxicities and no discontinuations due to TRAEs across doses up to 45 mg/day.
- Among 19 response-evaluable patients, tumor shrinkage was observed in 13 patients; 2 confirmed PRs and 1 unconfirmed PR.
- Most common TRAEs were dysgeusia (81% any grade), anemia (38% any grade; 6% grade 3), and neutropenia (34% any grade; 28% grade 3).
- 11 of 32 patients remain on treatment; longest treatment duration is 62 weeks.
- Data will be presented at ASCO on May 30, 2026; a Phase 3 OPERA-02 trial-in-progress poster will also be presented.
- OP-3136 is being evaluated in ER+/HER2- advanced breast cancer, mCRPC, and mNSCLC.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue.
Risk Factors
- Small sample size (32 patients, 19 evaluable) limits statistical reliability.
- Grade 3 neutropenia (28%) and anemia (6%) may become dose-limiting in larger cohorts.
- No revenue or near-term approval; company is pre-commercial and dependent on financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299773 |
Track record
20 reports on OLMA
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $7.27 Now $7.36 +1.24% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
- Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
- Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers